

REGULATION | POLICY | MARKET ACCESS

Sentinel and the Media: An Old Challenge, A New Opportunity

Michael McCaughan
Editor, The RPM Report
Founding Member, Prevision Policy
November 17, 2010

The Big Challenge Is The Same




- What Makes "News?"
 - Public Health Impact Is One Factor...
 - ...And Journalists WILL Play a Role
 - But Many Other Factors Count—Often For More
 - Deadlines and Space Considerations
 - Individual Interests (Stories Beget Stories)
 - Business Impact
 - Public Policy Impact
 - Desire for "Scoops"
 - Selling Subscriptions, Driving Ratings, Pleasing Funders

Secrecy Increases News Value

Health Headlines Aren't All About Health






News Amplifiers

- Investor Impact
 - Consider Byetta & Pancreatitis
- Product Liability Issues
 - Avandia vs. Meridia
- Political/Policy Agendas
 - Epidemiology vs. Clinical Trialists
- Score-Settling
- Publicity-Seeking
- Sheer Luck

Not All Brands Are "News"







Katie Couric & Steve Nissen


The *Vytorin* Experience

- Issue Was Handling of Failed Trial
- Brand Awareness Amplified News Value of the Story
- Compare to Lopid Helsinki II Study

New Issues




- It's A Computer...
 - So It Must Be Right
- It's The Government...
 - I Must Fear It
- It's My Data…
 - Leave it Alone



What About The Sponsor?





Pharma Sponsor No Longer at Center of Information Flow About Medicine

- Do They Get "Privileged" Access To Emerging Signals?
 - If So, THAT's A Story
 - If Not, They Are Still My First Call
- What if There are Multiple Affected Sponsors?

What if There is NO Center?


The Changing "News Cycle"





TripTik for Reporters

- "Dollars for Docs" database
- Look on State Medical Board sites
- Look for FDA Warning Letters, disqualifications
- County Courthouse for malpractice suits
- Interview docs: they often work for different companies: don't know how much they receive; on IRS filings



Source: Alicia Mundy

Closing Thoughts: A New Opportunity?



- Remember the Broader Context
 - Risk Communication Challenges Overall
 - New Regulatory Model (REMS, PMCs, etc.)
- Disclose EVERYTHING
 - Eliminates "Secrecy" As Headline Driver—and Exhausts Interest
 - Disclose Does NOT = Publicize
- Iterative Process is a Plus
 - As Long as There is a Conclusion

The Drug Approval Process Works: Public Uncertainty Precedes FDA Conclusion



REGULATION | POLICY | MARKET ACCESS

Questions?

Michael.McCaughan@previsionpolicy.com

202-747-9477